BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 11015546)

  • 1. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS).
    Braun MM; Mootrey GT; Salive ME; Chen RT; Ellenberg SS
    Pediatrics; 2000 Oct; 106(4):E51. PubMed ID: 11015546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS), 1996-1998.
    DuVernoy TS; Braun MM
    Pediatrics; 2000 Oct; 106(4):E52. PubMed ID: 11015547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of serious neurological disorders following immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines.
    Geier DA; Geier MR
    Brain Dev; 2004 Aug; 26(5):296-300. PubMed ID: 15165669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010.
    Moro PL; Yue X; Lewis P; Haber P; Broder K
    Vaccine; 2011 Nov; 29(50):9404-8. PubMed ID: 21920404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety Surveillance of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccines.
    Moro PL; Perez-Vilar S; Lewis P; Bryant-Genevier M; Kamiya H; Cano M
    Pediatrics; 2018 Jul; 142(1):. PubMed ID: 29866795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010-December 2018.
    Haber P; Moro PL; Ng C; Dores GM; Perez-Vilar S; Marquez PL; Cano M
    Vaccine; 2020 Feb; 38(6):1476-1480. PubMed ID: 31883809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005].
    van der Maas NA; David S; Kemmeren JM; Vermeer-de Bondt PE
    Ned Tijdschr Geneeskd; 2007 Dec; 151(49):2732-7. PubMed ID: 18225797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007.
    Chang S; O'Connor PM; Slade BA; Woo EJ
    Vaccine; 2013 Feb; 31(10):1447-52. PubMed ID: 23142308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT.
    Le Saux N; Barrowman NJ; Moore DL; Whiting S; Scheifele D; Halperin S;
    Pediatrics; 2003 Nov; 112(5):e348. PubMed ID: 14595075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of apnea, bradycardia, and desaturations following first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B immunization in hospitalized preterm infants.
    Lee J; Robinson JL; Spady DW
    BMC Pediatr; 2006 Jun; 6():20. PubMed ID: 16784533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of adverse effects following immunization with vaccine containing whole-cell vs. acellular pertussis components.
    Zieliński A; Rosińska M
    Przegl Epidemiol; 2008; 62(3):589-96. PubMed ID: 19108523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.
    Nolan T; Bernstein H; Blatter MM; Bromberg K; Guerra F; Kennedy W; Pichichero M; Senders SD; Trofa A; Collard A; Sullivan DC; Descamps D
    Pediatrics; 2006 Sep; 118(3):e602-9. PubMed ID: 16950952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serious neurological conditions following pertussis immunization: an analysis of endotoxin levels, the vaccine adverse events reporting system (VAERS) database and literature review.
    Geier DA; Geier MR
    Pediatr Rehabil; 2002; 5(3):177-82. PubMed ID: 12587565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of endotoxin concentrations in vaccines.
    Geier DA; Geier MR
    Ann Pharmacother; 2002 May; 36(5):776-80. PubMed ID: 11978151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment.
    Rosenthal S; Chen R; Hadler S
    Arch Pediatr Adolesc Med; 1996 May; 150(5):457-60. PubMed ID: 8620224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the effects of thimerosal on neurodevelopmental disorders reported following DTP and Hib vaccines in comparison to DTPH vaccine in the United States.
    Geier DA; Geier MR
    J Toxicol Environ Health A; 2006 Aug; 69(15):1481-95. PubMed ID: 16766480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.